Comparison of Propranolol versus Amitriptyline as monotherapy for migraine prophylaxis

Deepthi Rao  Gorukanti; Vallakoti Rajneesh; N Sumalatha; C h Karunakar

doi:10.53730/ijhs.v6nS1.6578

Authors

Deepthi Rao Gorukanti Associate Professor, Department of General Medicine, Surabhi Institute of Medical Sciences, Mittapally village, Siddipet MDL & Dist, Telangana State
Vallakoti Rajneesh Assistant Professor, Department of General Medicine, Surabhi Institute of Medical Sciences, Mittapally village, Siddipet MDL & Dist, Telangana State
N Sumalatha Assistant Professor, Department of General Medicine, RIMS, Adilabad¸Telangana State
Ch Karunakar Professor, Department of Medicine Surabhi Institute of Medical sciences, Mittapally village, Siddipet MDL & Dist, Telangana State

Keywords:

Propranolol, Amitriptyline, Migraine Prophylaxis, Migraine

Abstract

Introduction: Several drugs like Beta Blockers, SSRIs etc., are used for migraine prophylaxis. Objectives: The purpose of the present study was to compare the efficacy of propranolol and amitriptyline as monotherapy for the prophylaxis of migraine. Materials and Methods: This was a comparative, double-blinded, Prospective, randomized controlled study conducted at Department of General Medicine at Surabhi Institute of Medical Sciences. A total of 140 patients were enrolled in the study, diagnosed cases of migraine were randomly allocated using random number table to either Group 1 (Period 1: To receive tablet Propranolol 4–16 weeks and Period 2: Amitriptyline 20–32 weeks) or Group 2 (Period 1: To receive tablet Amitriptyline 4–16 weeks and Period 2: Propranolol 20–32 weeks). During the first 4 weeks, the run-in period, the patients do not receive prophylactic treatment and have to record in a headache diary the number of migraine attacks, the duration of attacks in hours and the severity. Similarly during 16 to 20 weeks patient didn’t receive any prophylactic treatment to wear of the drug effects.

Downloads

Download data is not yet available.

References

Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology. 2000;55(9 Suppl 2):S29-35.

Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41:646-657.

Habib M et al. Headache, study of 3350 cases. Bangladesh J Neuroscience. 2001; 17(1):1-5.

Bigal ME, Krymchantowski AV, Rapoport AM. Prophylactic migraine therapy: emerging treatment options. Curr Pain Headache Rep 2004; 8:178–84.

Steiner TJ, Stovner LJ, Birbeck GL. (2013) Migraine: the seventh disabler. J Headache Pain 2013; 14(1): 1.

Martelletti P, Birbeck GL, Katsarava Z, Jensen RH, Stovner LJ, Steiner TJ. The Global Burden of Disease survey 2010, lifting the Burden and thinking outside-the-box on headache disorders. J Headache Pain 2013; 14(1): 13.

Oldenmenger WH, de Raaf PJ, de Klerk C, van der Rijt CC. Cut points on 0-10 numeric rating scales for symptoms included in the Edmonton Symptom Assessment Scale in cancer patients: a systematic review. J Pain Symptom Manage 2013; 45(6): 1083-93.

Cady RK, Schreiber CP, Porter JAH, Blumenfeld AM, Farmer KU. A Multi-Center Double-Blind Pilot Comparison of Onabotulinumtoxin A and Topiramate for the Prophylactic Treatment of Chronic Migraine. Headache 2011; 51: 21-32.

Couch JR, Amitriptyline Versus Placebo Study Group Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 2011; 51(1):33–51.

Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ Apr 2010; 182(7): E269-76.

Pryse-Phillips, William (2003). Companion to clinical neurology (2nd Ed.). Oxford: Oxford university press. p. 587. ISBN 9780195159387. Archived from the original on 2017-03-13.

Bartleson JD, Cutrer FM (May 2010). "Migraine update. Diagnosis and treatment". Minn Med. 93 (5): 36–41.

Schürks, M (January 2012). "Genetics of migraine in the age of genome-wide association studies". The journal of headache and pain. 13 (1): 1–9.

Shevel, E (March 2011). "The extracranial vascular theory of migraine – a great story confirmed by the facts". Headache. 51 (3): 409–17.

Loder, E; Burch, R; Rizzoli, P (June 2012). "The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines". Headache. 52 (6): 930–45.

Lipton, R.B., W.F. Stewart and S. Diamond, 2001. Prevalence and burden of migraine in the United States: Data from the American migraine study II. Headache, 41: 646-57.

Chowdhury D, Mundra A. Role of greater occipital nerve block for preventive treatment of chronic migraine: A critical review. Cephalalgia Rep 2020;3:25158.

Krymchantowski AV, da Cunha JC, Bigal ME (2012) Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. J Headache Pain 13: 53–59.

Tomkins GE, Jackson JL, O'Malley PG, Balden E, Santoro JE (2001) Treatment of chronic headache with antidepressants: a meta-analysis. Am J Med 111: 54–63.

Linde K, Rossnagel K (2004) Propranolol for migraine prophylaxis. Cochrane Database Syst Rev CD003225.

Mulleners WM, McCrory DC, Linde M (2014) Antiepileptics in migraine prophylaxis: An updated Cochrane review. Cephalalgia. 0333102414534325 [pii].

Peterlin BL, Calhoun AH, Siegel S, Mathew NT. Rational combination therapy in refractory migraine. Headache 2008;48:805-819.

Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, Diemer M, et al. (2010) Tricyclic antide-pressants and headaches: systematic review and meta-analysis.

Bordini CA, et al. Burden of migraine in Brazil: estimate of cost of migraine to the public health system and an analytical study of the cost-effectiveness of a stratified model of care. Headache 2003;43:742-754.

Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 2020;40:241-54.

Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): A randomised, double blind, placebo-controlled, phase 3b trial. Lancet 2019;394:1030-40.

Moja PL, Cusi C, Sterzi RR, Canepari C (2005) Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev CD002919.

Shamliyan TA, Choi JY, Ramakrishnan R, Miller JB, Wang SY, Taylor FR, et al. (2013) Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med 28: 1225–1237.